Aprea Therapeutics signs securities purchase agreement for $0.89 per share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 30 Jan 26
Aprea Therapeutics Inc. has seen a significant price increase of 42.51% as it crosses above the 5-day SMA, indicating strong market interest.
The company announced a securities purchase agreement with healthcare-focused institutional investors to sell 6.29 million shares at $0.89 each, with warrants exercisable at $0.765. This proactive financing effort aims to support liquidity and fund research and development, despite a 7.83% drop in stock price following the announcement, suggesting a cautious market reaction to the financing strategy.
This agreement may provide Aprea with the necessary capital to continue its innovation and business development, positioning the company for potential future growth.
Analyst Views on APRE
Wall Street analysts forecast APRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APRE is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.796
Low
5.00
Averages
5.00
High
5.00
Current: 0.796
Low
5.00
Averages
5.00
High
5.00
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
